One fifth of Europe's biopharma firms "at risk of bankruptcy"
This article was originally published in Scrip
Executive Summary
The European biotechnology industry is calling for urgent action at both EU and national levels after a new study suggested that a fifth of small European biopharmaceutical companies could be facing bankruptcy by the end of the year as a result of the global financial crisis.